News

Previous studies had demonstrated that VeloThrax also possesses enhanced thermostability, enabling distribution without cold chain requirements. VeloThrax is the Company’s proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant

ORBACTIV is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the ORBACTIV treatment regimen

Streptococcus pneumonia (pneumococcus) is a gram-positive, alpha-hemolytic, aerotolerant, aerobic member of the genus Streptococcus. Currently, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is approved for adults in

Under the deal, Liaison will deliver its data services to customers in the healthcare industry on ClearDATA’s HIPAA-compliant cloud platform. The deal will see Liaison become a referral

The new patent will extend coverage to include a significantly broader gamut of chemical compounds, which the company might develop as immune-modulating drugs targeting an inflammatory pathway involved

Under the deal, Yabao secured exclusive rights to develop and commercialize LS-008 in China while Le Sun retains majority of exclusive rights in all other markets. Both the

The contract includes performing studies on the vaccine that has been licensed from the Public Health Agency of Canada, to move it closer to human clinical trials. The

Currently, the company is developing TRV734 to optimize analgesia while reducing on-target gastrointestinal and central nervous system adverse effects through its new biased ligand mechanism at the mu-opioid

The studies were conducted by Professor Paul Quax, Ph.D., and Yaël Nossent, Ph.D., of the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center